NEW YORK (GenomeWeb News) – Nanosphere said today that its second quarter revenues jumped 38 percent year over year, with the rise being driven by sales of its Verigene Gram-Positive Blood Culture Test.

Nanosphere also lowered its revenue guidance for the year as well as its expectations for instrument placements. In response, its shares plummeted around 32 percent to $2.00 in Wednesday morning trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.